Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study

BACKGROUND: Recombinant human endostatin (rh-endostatin) is a novel antiangiogenesis drug developed in China. Previous experiments have shown that rh-endostatin can inhibit the proliferation and migration of endothelial cells and some types of tumor cells. In this study, we evaluated the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jianghao, Yao, Qing, Li, Dong, Zhang, Juliang, Wang, Ting, Yu, Ming, Zhou, Xiaodong, Huan, Yi, Wang, Jing, Wang, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664086/
https://www.ncbi.nlm.nih.gov/pubmed/23693018
http://dx.doi.org/10.1186/1471-2407-13-248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664086/
https://www.ncbi.nlm.nih.gov/pubmed/23693018
http://dx.doi.org/10.1186/1471-2407-13-248

Ejemplares similares